Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.58 |
| ▸ | MGLL | Q99685 | 2/20 | 0.57 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5486014 | 1.00 | HSD11B1 (0.58) | HSD11B1MGLLKDM2BALDH1A1L3MBTL1 | |
| SCHEMBL21926418 | 0.96 | HSD11B1 (0.58) | HSD11B1MGLLKDM2BALDH1A1L3MBTL1 | |
| SCHEMBL5473312 | 0.91 | ALDH1A1 (0.52) | HSD11B1ALDH1A1L3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL5473320 | 0.91 | ALDH1A1 (0.52) | HSD11B1ALDH1A1L3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL5470739 | 0.88 | MEN1 (0.61) | HSD11B1MGLLKDM2BALDH1A1LMNA | |
| SCHEMBL5470746 | 0.88 | MEN1 (0.61) | HSD11B1MGLLKDM2BALDH1A1LMNA | |
| SCHEMBL5473979 | 0.87 | ALDH1A1 (0.66) | HSD11B1ALDH1A1L3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL5473981 | 0.87 | ALDH1A1 (0.66) | HSD11B1ALDH1A1L3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL21926568 | 0.86 | HSD11B1 (0.53) | HSD11B1KDM2BALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL21926550 | 0.84 | HSD11B1 (0.70) | HSD11B1MGLLKDM2BALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112000-A1 | Chemical compounds | ASTRAZENECA R&D ALDERLEY (GB) | 2007-05-17 | — | — | US | claimed |
| EP-1684757-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | AstraZeneca AB (SE) | 2006-08-02 | — | — | EP | claimed |
| WO-2005046685-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112000-A1 | Chemical compounds | HSD11B1, CYP11B1, HSD11B2 | HSD11B1 1/4885MGLL 630/4885KDM2B 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.